{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T18:03:30Z","timestamp":1771869810082,"version":"3.50.1"},"reference-count":47,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,9,3]],"date-time":"2010-09-03T00:00:00Z","timestamp":1283472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovascular Therapeutics"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:p>The last decade has seen major advances in the pharmacotherapy of pulmonary arterial hypertension (PAH). One of these advances has been the discovery of endothelin receptor antagonists (ERAs). ERAs are a class of potent vasodilators and antimitotic substances, which could specifically dilate and remodel pulmonary arterial system, and have been proposed as an alternative to traditional therapies for PAH. Current available evidence suggests that ERAs improve exercise capacity, functional status, pulmonary hemodynamics, and delay the time to clinical worsening for patients with PAH. This review attempts to provide an overview of the pharmacology, therapeutic benefits, and safety profile of ERAs in patients with PAH.<\/jats:p>","DOI":"10.1111\/j.1755-5922.2010.00158.x","type":"journal-article","created":{"date-parts":[[2010,4,9]],"date-time":"2010-04-09T14:26:45Z","timestamp":1270823205000},"source":"Crossref","is-referenced-by-count":17,"title":["REVIEW: Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension: An Overview"],"prefix":"10.1111","volume":"28","author":[{"given":"Shahzad G.","family":"Raja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,9,3]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2003.11.026"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701093360207"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.114.3_Supplement.184S"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1233306"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-5-343"},{"key":"e_1_2_8_7_2","first-page":"265","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension","volume":"2","author":"Casserly B","year":"2009","journal-title":"Drug Des Devel Ther"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1078\/0344-0338-00273"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1139\/y02-025"},{"key":"e_1_2_8_10_2","first-page":"653","article-title":"Profile of past and current clinical trials involving endothelin receptor antagonists: The novel \u201c\u2010sentan\u201d class of drug","volume":"231","author":"Battistini B","year":"2006","journal-title":"Exp Biol Med (Maywood)"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X158020"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(98)00347-6"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S2270"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.4103\/0971-9784.38443"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C256"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443150-00003"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm9700068"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1586\/14779072.3.6.985"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm030528p"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.04.050"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.05.005"},{"key":"e_1_2_8_22_2","first-page":"11","article-title":"A review of pulmonary arterial hypertension: Role of ambrisentan","volume":"3","author":"Barst RJ","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200307-957OC"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.01.057"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02383.x"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0408-z"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00138706"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.4_MeetingAbstracts.254S-c"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.4_MeetingAbstracts.256S-b"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.04.050"},{"key":"e_1_2_8_31_2","first-page":"A728","article-title":"Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension: Results of the ARIES\u20102 study","volume":"3","author":"Olschewski H","year":"2006","journal-title":"Proc Am Thorac Soc"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.4_MeetingAbstracts.121S-a"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.742510"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012212"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00028404"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.630715"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06250-X"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60919-8"},{"key":"e_1_2_8_39_2","unstructured":"European Medicines Agency.EPARs for authorised medicinal products for human use: Thelin.European Public Assessment Report.http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/thelin\/H\u2010679\u2010en6.pdf(Accessed December222009)."},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200410-1411OC"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004434.pub4"},{"key":"e_1_2_8_42_2","first-page":"A729","article-title":"Chronic treatment of pulmonary arterial hypertension (PAH) with sitaxentan and bosentan","volume":"3","author":"Benza RL","year":"2006","journal-title":"Proc Am Thorac Soc"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn234"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.114667"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00107-1"},{"key":"e_1_2_8_46_2","first-page":"1","article-title":"Ambrisentan, darusentan, bosentan, and sitaxsentan: Differences in inhibition of hepatobilliary transporters in two species","volume":"39","author":"Brouwer KR","year":"2007","journal-title":"Drug Metab Rev"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-1028"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0890-6238(98)00064-1"}],"container-title":["Cardiovascular Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-5922.2010.00158.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1755-5922.2010.00158.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T20:28:54Z","timestamp":1698784134000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-5922.2010.00158.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,3]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1755-5922.2010.00158.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1755-5922.2010.00158.x","archive":["Portico"],"relation":{},"ISSN":["1755-5914","1755-5922"],"issn-type":[{"value":"1755-5914","type":"print"},{"value":"1755-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,3]]}}}